Cyprotex - News
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

French Research Tax Credit Accreditation

Cyprotex Discovery Receives French Research Tax Credit Accreditation

Cyprotex (AIM:CRX), the drug discovery technology and information company, is pleased to announce that it has received French research tax credit approval for years 2009 through to 2011.

The French Ministry of Research (Ministère de l'Enseignement Supérieur et de la Recherche) has granted the French R&D tax credit ("Crédit d'Impôt Recherche", CIR) accreditation to Cyprotex as of March 2010. This initiative allows eligible French pharmaceutical, biotech and agricultural companies subject to corporate tax in France, the ability to claim significant tax relief on costs generated in R&D requirements that are outsourced to Cyprotex Discovery.

Dr Anthony Baxter, Cyprotex's Chief Executive Officer, comments: 'We are delighted to receive this recognition and approval from the French Ministry of Research which will provide greater opportunities to support our current client base and allow for improved collaborations with future French clients.'

Additional information on the French research tax credit system is available from the Ministère de l'Enseignement Supérieur et de la Recherche site -

For further information:
Cyprotex PLC
Dr. Anthony Baxter, Chief Executive Officer
Tel: +44 1625 505 100

Execution Noble & Company Limited
John Llewellyn-Lloyd
Sam Reynolds
Tel: 020 7456 9191

Public Relations
Financial Dynamics

Ben Brewerton
Ben Atwell
Mo Noonan
Tel: 020 7831 3113

Contact us

News categories


Contact us to discuss your ADME Tox issues or request a quote

North America (East Coast): 888-297-7683
Europe: +44 1625 505100


or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.